vs
Side-by-side financial comparison of AMICUS THERAPEUTICS, INC. (FOLD) and COMSCORE, INC. (SCOR). Click either name above to swap in a different company.
AMICUS THERAPEUTICS, INC. is the larger business by last-quarter revenue ($185.2M vs $93.5M, roughly 2.0× COMSCORE, INC.). COMSCORE, INC. runs the higher net margin — 3.2% vs 0.9%, a 2.3% gap on every dollar of revenue. On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs -1.5%). AMICUS THERAPEUTICS, INC. produced more free cash flow last quarter ($16.0M vs $2.9M). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs 3.8%).
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
Comscore, Inc. is an American-based global media measurement and analytics company providing marketing data and analytics to enterprises, advertising agencies, brand marketers, and publishers.
FOLD vs SCOR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $185.2M | $93.5M |
| Net Profit | $1.7M | $3.0M |
| Gross Margin | 85.7% | 41.0% |
| Operating Margin | 8.6% | 7.0% |
| Net Margin | 0.9% | 3.2% |
| Revenue YoY | 23.7% | -1.5% |
| Net Profit YoY | -88.5% | -3.7% |
| EPS (diluted) | $0.00 | $9.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $185.2M | $93.5M | ||
| Q3 25 | $169.1M | $88.9M | ||
| Q2 25 | $154.7M | $89.4M | ||
| Q1 25 | $125.2M | $85.7M | ||
| Q4 24 | $149.7M | $94.9M | ||
| Q3 24 | $141.5M | $88.5M | ||
| Q2 24 | $126.7M | $85.8M | ||
| Q1 24 | $110.4M | $86.8M |
| Q4 25 | $1.7M | $3.0M | ||
| Q3 25 | $17.3M | $453.0K | ||
| Q2 25 | $-24.4M | $-9.5M | ||
| Q1 25 | $-21.7M | $-4.0M | ||
| Q4 24 | $14.7M | $3.1M | ||
| Q3 24 | $-6.7M | $-60.6M | ||
| Q2 24 | $-15.7M | $-1.7M | ||
| Q1 24 | $-48.4M | $-1.1M |
| Q4 25 | 85.7% | 41.0% | ||
| Q3 25 | 88.5% | 40.6% | ||
| Q2 25 | 90.2% | 40.6% | ||
| Q1 25 | 90.7% | 39.6% | ||
| Q4 24 | 90.1% | 42.4% | ||
| Q3 24 | 90.6% | 41.2% | ||
| Q2 24 | 91.1% | 39.5% | ||
| Q1 24 | 87.7% | 42.3% |
| Q4 25 | 8.6% | 7.0% | ||
| Q3 25 | 20.3% | 1.9% | ||
| Q2 25 | -6.1% | -1.9% | ||
| Q1 25 | -6.3% | -2.4% | ||
| Q4 24 | 10.7% | 4.1% | ||
| Q3 24 | 15.3% | -67.4% | ||
| Q2 24 | 11.8% | -2.2% | ||
| Q1 24 | -25.1% | -2.2% |
| Q4 25 | 0.9% | 3.2% | ||
| Q3 25 | 10.2% | 0.5% | ||
| Q2 25 | -15.8% | -10.6% | ||
| Q1 25 | -17.3% | -4.7% | ||
| Q4 24 | 9.8% | 3.3% | ||
| Q3 24 | -4.8% | -68.5% | ||
| Q2 24 | -12.4% | -2.0% | ||
| Q1 24 | -43.9% | -1.2% |
| Q4 25 | $0.00 | $9.50 | ||
| Q3 25 | $0.06 | $-0.86 | ||
| Q2 25 | $-0.08 | $-2.73 | ||
| Q1 25 | $-0.07 | $-1.66 | ||
| Q4 24 | $0.05 | $-0.47 | ||
| Q3 24 | $-0.02 | $-12.79 | ||
| Q2 24 | $-0.05 | $-1.19 | ||
| Q1 24 | $-0.16 | $-1.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $293.5M | $23.6M |
| Total DebtLower is stronger | $392.7M | $41.5M |
| Stockholders' EquityBook value | $274.2M | $111.4M |
| Total Assets | $949.9M | $407.7M |
| Debt / EquityLower = less leverage | 1.43× | 0.37× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $293.5M | $23.6M | ||
| Q3 25 | $263.8M | $26.7M | ||
| Q2 25 | $231.0M | $26.0M | ||
| Q1 25 | $250.6M | $31.0M | ||
| Q4 24 | $249.9M | $29.9M | ||
| Q3 24 | $249.8M | $20.0M | ||
| Q2 24 | $260.1M | $14.7M | ||
| Q1 24 | $239.6M | $18.7M |
| Q4 25 | $392.7M | $41.5M | ||
| Q3 25 | $392.0M | $41.4M | ||
| Q2 25 | $391.3M | $41.3M | ||
| Q1 25 | $390.7M | $41.3M | ||
| Q4 24 | $390.1M | $41.2M | ||
| Q3 24 | $389.5M | — | ||
| Q2 24 | $388.9M | — | ||
| Q1 24 | $388.4M | — |
| Q4 25 | $274.2M | $111.4M | ||
| Q3 25 | $230.4M | $-26.3M | ||
| Q2 25 | $204.3M | $-21.7M | ||
| Q1 25 | $193.6M | $-13.5M | ||
| Q4 24 | $194.0M | $-8.3M | ||
| Q3 24 | $178.8M | $-2.7M | ||
| Q2 24 | $132.5M | $45.8M | ||
| Q1 24 | $130.7M | $51.4M |
| Q4 25 | $949.9M | $407.7M | ||
| Q3 25 | $868.8M | $406.9M | ||
| Q2 25 | $815.3M | $415.9M | ||
| Q1 25 | $789.8M | $421.5M | ||
| Q4 24 | $785.0M | $430.2M | ||
| Q3 24 | $786.6M | $412.5M | ||
| Q2 24 | $749.5M | $474.1M | ||
| Q1 24 | $721.8M | $477.7M |
| Q4 25 | 1.43× | 0.37× | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 1.92× | — | ||
| Q1 25 | 2.02× | — | ||
| Q4 24 | 2.01× | — | ||
| Q3 24 | 2.18× | — | ||
| Q2 24 | 2.93× | — | ||
| Q1 24 | 2.97× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.3M | $3.2M |
| Free Cash FlowOCF − Capex | $16.0M | $2.9M |
| FCF MarginFCF / Revenue | 8.6% | 3.1% |
| Capex IntensityCapex / Revenue | 0.2% | 0.3% |
| Cash ConversionOCF / Net Profit | 9.62× | 1.07× |
| TTM Free Cash FlowTrailing 4 quarters | $29.8M | $21.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.3M | $3.2M | ||
| Q3 25 | $35.7M | $9.5M | ||
| Q2 25 | $-26.5M | $932.0K | ||
| Q1 25 | $7.8M | $9.1M | ||
| Q4 24 | $-3.9M | $-10.0M | ||
| Q3 24 | $-23.0M | $12.5M | ||
| Q2 24 | $22.7M | $8.7M | ||
| Q1 24 | $-29.7M | $6.9M |
| Q4 25 | $16.0M | $2.9M | ||
| Q3 25 | $35.3M | $9.4M | ||
| Q2 25 | $-28.9M | $787.0K | ||
| Q1 25 | $7.5M | $8.7M | ||
| Q4 24 | $-4.2M | $-10.3M | ||
| Q3 24 | $-23.3M | $12.4M | ||
| Q2 24 | $21.6M | $8.5M | ||
| Q1 24 | $-31.5M | $6.6M |
| Q4 25 | 8.6% | 3.1% | ||
| Q3 25 | 20.9% | 10.5% | ||
| Q2 25 | -18.7% | 0.9% | ||
| Q1 25 | 6.0% | 10.1% | ||
| Q4 24 | -2.8% | -10.8% | ||
| Q3 24 | -16.5% | 14.0% | ||
| Q2 24 | 17.0% | 10.0% | ||
| Q1 24 | -28.5% | 7.6% |
| Q4 25 | 0.2% | 0.3% | ||
| Q3 25 | 0.2% | 0.1% | ||
| Q2 25 | 1.6% | 0.2% | ||
| Q1 25 | 0.2% | 0.4% | ||
| Q4 24 | 0.2% | 0.2% | ||
| Q3 24 | 0.3% | 0.1% | ||
| Q2 24 | 0.9% | 0.2% | ||
| Q1 24 | 1.6% | 0.3% |
| Q4 25 | 9.62× | 1.07× | ||
| Q3 25 | 2.06× | 20.96× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -0.27× | -3.19× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
SCOR
| Transferred Over Time | $77.1M | 83% |
| Research Insight Solutions | $14.6M | 16% |
| Related Party | $2.5M | 3% |
